Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited announced that its Aminophylline Tablets have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, as approved by the National Medical Products Administration. This approval is a significant milestone for the company, potentially enhancing its market position by ensuring the quality and efficacy of its generic drugs, which could lead to increased trust and demand from healthcare providers and patients.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in China, operating within the pharmaceutical industry. The company focuses on the production and distribution of prescription drugs, with a particular emphasis on chemical-based medications.
YTD Price Performance: -7.75%
Average Trading Volume: 2,131,863
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.24B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.